Covered recipient · General Payments record
ASHLEY STUTES
General Payments · PY2024–2025
$257.25
- Reported across 11 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $215.85 | 9 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| LivaNova USA, Inc. | $73.84 | 2 |
| Neurocrine BioSciences, Inc. | $29.77 | 1 |
| UCB, Inc. | $23.94 | 1 |
| Teva Pharmaceuticals USA, Inc. | $21.05 | 1 |
| Janssen Pharmaceuticals, Inc | $19.85 | 1 |
| CSL Behring | $17.08 | 1 |
| E.R. Squibb & Sons, L.L.C. | $15.28 | 1 |
| ITI, Inc. | $15.04 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (9)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| CSL Behring | $17.08 | 05/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1232377546 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.28 | 04/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1184399408 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.04 | 04/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241408386 | CMS |
| Janssen Pharmaceuticals, Inc | $19.85 | 04/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174530637 | CMS |
| LivaNova USA, Inc. | $42.07 | 02/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1245685533 | CMS |
| LivaNova USA, Inc. | $31.77 | 04/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1245685674 | CMS |
| Neurocrine BioSciences, Inc. | $29.77 | 12/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1242988547 | CMS |
| Teva Pharmaceuticals USA, Inc. | $21.05 | 04/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247413282 | CMS |
| UCB, Inc. | $23.94 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224483030 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2024, 2025
- Source files
- Dataset page · Bulk file · PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.